Valuation: Thalia Therapeutics Plc

Market Cap 11.1M 14.71M 13.13M 12.2M 20.88M 1.39B 21.26M 147M 57.34M 727M 55.19M 54.02M 2.33B P/E 2024
-1.69x
P/E 2025 -3.09x
Enterprise Value 10.02M 13.28M 11.85M 11.01M 18.85M 1.26B 19.19M 132M 51.77M 656M 49.82M 48.77M 2.1B EV / Sales 2024
198,657,512x
EV / Sales 2025 452,941,079x
Free-Float
41.35%
Yield 2024 *
-
Yield 2025 -
1 month+13.64%
3 months-3.85%
Current year+19.05%
1 week 0.6
Extreme 0.6
0.65
1 month 0.55
Extreme 0.55
0.65
Current year 0.4
Extreme 0.4
0.95
1 year 0.4
Extreme 0.4
0.95
3 years 0.35
Extreme 0.35
1.5
5 years 0.35
Extreme 0.35
8.69
10 years 0.35
Extreme 0.35
35.7
Manager TitleAgeSince
Chief Executive Officer 66 2026-02-23
Chief Operating Officer - -
Chief Tech/Sci/R&D Officer 56 2025-05-26
Director TitleAgeSince
Director/Board Member 48 2020-07-13
Chairman 59 2023-07-31
Director/Board Member 81 2024-09-08
Date Insider Type Main position Quantity % Market Cap. Importance
11/28/24 Free

Founder

6,000,000 1.5198%
11/28/24 Free

Director

3,000,000 0.7599%
11/28/24 Free

Chairman

3,000,000 0.7599%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+4.17%-34.21% 14.59M
+0.21%-7.67%+61.07%+71.32% 68.92B
+1.66%-9.54%+10.39%+60.04% 51.9B
+3.14%+4.61%+15.36%+44.42% 48.73B
+3.45%+5.01%+32.37%+35.96% 43.13B
-2.20%-5.78%+298.44%+532.76% 41.48B
+6.43%+2.76%+16.56%+109.23% 39.96B
+1.28%-0.76%+12.67%+45.10% 30.6B
-2.21%-14.22%+40.33%-0.94% 26.01B
+1.74%-5.30%-12.09%-12.92% 22.27B
Average +1.35%-3.51%+47.93%+85.08% 37.3B
Weighted average by Cap. +1.58%-3.49%+56.57%+105.30%

Financials

2024 2025
Net sales 0.01 0.01 0.01 0.01 0.01 0.91 0.01 0.1 0.04 0.48 0.04 0.04 1.53 0.01 0.01 0.01 0.01 0.01 0.91 0.01 0.1 0.04 0.48 0.04 0.04 1.52
Net income -1.06M -1.4M -1.25M -1.16M -1.99M -133M -2.03M -13.98M -5.47M -69.33M -5.26M -5.15M -222M -1.21M -1.6M -1.43M -1.32M -2.27M -151M -2.31M -15.91M -6.23M -78.91M -5.99M -5.87M -253M
Net Debt -626K -830K -740K -688K -1.18M -78.57M -1.2M -8.27M -3.23M -40.99M -3.11M -3.05M -131M -1.08M -1.43M -1.28M -1.19M -2.03M -135M -2.07M -14.25M -5.58M -70.68M -5.37M -5.25M -226M
Projected Income Statement - Annual - Thalia Therapeutics Plc
Logo Thalia Therapeutics Plc
Thalia Therapeutics PLC, formerly N4 Pharma plc, is a biotechnology company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. The Company is developing proprietary RNA delivery technologies (Nuvec) designed to enable multi-RNA loading, flexible targeting and the potential for oral delivery. Nuvec is based on amorphous silica and has an irregular surface structure that simply and effectively traps and protects RNA as it travels to target cells. The Nuvec delivery system can be functionalized by attaching a wide range of proteins, peptides, antibodies or radionuclides for therapeutic purposes. The Company has a growing pipeline of RNA-based programs across oncology and cardiovascular disease, including Dual-target cardiovascular siRNA program and Proprietary RNA delivery technology. The Company is advancing a novel long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein.
Employees
3
Date Price Change Volume
26-10-15 GBX 0.6250 0.00% 31,492
26-10-14 GBX 0.6250 0.00% 1,000,347
26-10-13 GBX 0.6250 0.00% 65,193
26-10-12 GBX 0.6250 0.00% 49,664
26-10-09 GBX 0.6250 0.00% 9,116
  1. Stock Market
  2. Stocks
  3. THAT Stock